This study will evaluate the effect of GS-6615 in adults with chronic stable angina and coronary artery disease (CAD) receiving a stable daily dose of up to 2 antianginal medications. The study will consist of two periods: a 1 to 3 week Qualifying Period and a Treatment Period lasting 13 days (± 3 days). During the Qualifying Period and at the end of the Treatment Period, participants will undergo exercise tolerance testing.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Change from baseline in time to 1 mm ST-segment depression
For treadmill-related endpoints, baseline is defined as the value derived from the last exercise tolerance testing performed during the qualifying period.
Time frame: Baseline; Day 13 (± 3 days)
Change from baseline in total exercise duration at the end of the double-blind treatment period
Time frame: Baseline; Day 13 (± 3 days)
Time to onset of angina during exercise tolerance testing at the end of the double-blind treatment period
Time frame: Baseline; Day 13 (± 3 days)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.